Condition: Gastric Adenocarcinoma · Gastroesophageal Junction (GEJ) Adenocarcinoma · Pancreatic Adenocarcinoma · Sponsor: Astellas Pharma Global Development, Inc.
Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a protein on a type of immune cell called a T-cell. This "tells" the immune system to attack the tumor. ASP2138 is a potential treatment for people with stomach cancer, gastroesophageal junction cancer (GEJ cancer) or pancreatic cancer. GEJ is where the tube that carries food (esophagus) joins the stomach. Before ASP2138 is available as a treatment, the researchers need to understand how it is processed by and acts upon the body. In this study, ASP2138 will either be given by itself, or given together with standard treatments for gastric, GEJ and pancreatic cancer. Pembrolizumab and mFOLFOX6, and ramucirumab and paclitaxel are standard treatments for gastric and GEJ cancer. mFOLFIRINOX is a standard treatment for pancreatic cancer. This information will help find a suitable dose of ASP2138 given by itself and together with the standard cancer treatments and to check for potential medical problems from the treatments. The main aims of the study are: * To check the safety of ASP2138 and how well people can tolerate medical problems during the study. * To find a suitable dose of ASP2138 to be used later in the study. * These are done for ASP2138 given by itself and when given together with the standard cancer treatments. Adults 18 years or ol…
This description comes directly from the study's public registry record.
Astellas Pharma Global Development, Inc. · 800-888-7704 · Astellas.registration@astellas.com
Always discuss trial participation with your own doctor first.
| University of California Irvine Medical Center | Orange, California, United States | Recruiting |
| UCLA Dept of Medicine - Hematology/Oncology, Santa Monica | Santa Monica, California, United States | Withdrawn |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| University of Kansas Cancer Center | Westwood, Kansas, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | Completed |
| NYU Langone Medical Center - NYU Medical Oncology Associates | New York, New York, United States | Recruiting |
| Columbia University | New York, New York, United States | Active Not Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Duke Children's Hospital and Health Center | Durham, North Carolina, United States | Recruiting |
| Wake Forest University Baptist Health | Winston-Salem, North Carolina, United States | Recruiting |
| UT Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| Virginia Mason Medical Center | Seattle, Washington, United States | Recruiting |
+ 34 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05365581